Skip to main content
Retour
Watch Compare

REGENEREX PHARMA, INC.

Qualité des données : 67%
RGPX
OTC Manufacturing Chemicals

Quick Summary

Points Clés

Negative free cash flow of -1,33 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,01
Interest Coverage-33,24

Valorisation

P/E Ratio
N/A
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E — -1,5
P/B — 1,6
ROE % — -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -4,49 M
ROE N/A ROA -710,39%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1,33 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,01
Interest Coverage -33,24 Asset Turnover N/A
Working Capital -4,88 M Tangible Book Value -4,70 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap N/A Enterprise Value N/A
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29,57%
SBC-Adj. FCF -1,84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2019
Revenue — — — 2 608,0 2 608,0
Net Income -3,54 M -137 330,0 -195 591,0 111 589,0 -93 579,0
EPS (Diluted) — — — — —
Gross Profit — — — 896,0 896,0
Operating Income -3,47 M -96 171,0 -126 267,0 -77 003,0 -91 734,0
EBITDA — — — — —
R&D Expenses 2,40 M 2,40 M — — —
SG&A Expenses 1,07 M — — — —
D&A — — — — —
Interest Expense 80 638,0 66 788,0 59 063,0 28 658,0 778,0
Income Tax -2 717,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2019
Total Assets 766 680,0 6 539,0 15 322,0 259 167,0 105 623,0
Total Liabilities 4,83 M 1,13 M 1,00 M 740 441,0 475 308,0
Shareholders' Equity -4,06 M -1,12 M -985 617,0 -481 274,0 -369 685,0
Total Debt 184 232,0 184 232,0 — — —
Cash & Equivalents 372,0 1 135,0 2 640,0 5 460,0 88 546,0
Current Assets 2 912,0 1 135,0 7 896,0 252 151,0 97 616,0
Current Liabilities 3,84 M 776 782,0 660 453,0 518 718,0 405 308,0